Disease-modifying therapies in relapsing&ndash;remitting multiple sclerosis

Código QR

Disease-modifying therapies in relapsing&ndash;remitting multiple sclerosis

Fabricio Gonz&aacute;lez-Andrade1, Jos&eacute; Luis Alcaraz-Alvarez21Department of Medicine, Metropolitan Hospital, Quito, Ecuador; 2School of Medicine, University of Mayab, Merida, MexicoClinical question: What is the best current disease-modifying therapy for relapsing&ndas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fabricio Gonz&aacute;lez-Andrade, Jos&eacute; Luis Alcaraz-Alvarez
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/3ef9b5d463c240cb9e420f541e6d9173
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing&ndash;remitting multiple sclerosis?
por: Mezei Z, et al.
Publicado: (2012)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi A, et al.
Publicado: (2013)

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
por: Julie A Murphy, et al.
Publicado: (2010)

Disconnection of the hippocampus and amygdala associated with lesion load in relapsing–remitting multiple sclerosis: a structural and functional connectivity study
por: Zhou F, et al.
Publicado: (2015)

Altered intra- and interregional synchronization in relapsing–remitting multiple sclerosis: a resting-state fMRI study
por: Wu L, et al.
Publicado: (2016)

Synchronization within, and interactions between, the default mode and dorsal attention networks in relapsing-remitting multiple sclerosis
por: Huang M, et al.
Publicado: (2018)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey D, et al.
Publicado: (2015)

Functional cortical changes in relapsing-remitting multiple sclerosis at amplitude configuration: a resting-state fMRI study
por: Liu H, et al.
Publicado: (2016)

Assessing Lumbar Plexus and Sciatic Nerve Damage in Relapsing-Remitting Multiple Sclerosis Using Magnetisation Transfer Ratio
por: Ratthaporn Boonsuth, et al.
Publicado: (2021)

The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis
por: Aliza Bitton Ben-Zacharia, et al.
Publicado: (2021)

Cognitive functioning and subjective quality of life in relapsing-remitting multiple sclerosis patients before and after percutaneous transluminal angioplasty: a preliminary report
por: De Pasquale C, et al.
Publicado: (2014)

CELLULAR IMMUNITY PARAMETERS IN PATIENTS WITH REMITTING MULTIPLE SCLEROSIS
por: I. P. Ivanova, et al.
Publicado: (2021)

Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey
por: Gross HJ, et al.
Publicado: (2017)

Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
por: Karl E. Carlström, et al.
Publicado: (2019)

Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis.
por: Henrik Lund, et al.
Publicado: (2013)

Secondary progressive and relapsing remitting multiple sclerosis leads to motor-related decreased anatomical connectivity.
por: Mark Lyksborg, et al.
Publicado: (2014)

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
por: Anne Waschbisch, et al.
Publicado: (2011)

Did depressive symptoms affect recognition of emotional prosody in Parkinson&rsquo;s disease?
por: Adriana V&eacute;lez Feij&oacute;, et al.
Publicado: (2008)

Beals&ndash;Hecht syndrome and choroidal neovascularization
por: Roberto Gallego-Pinazo, et al.
Publicado: (2010)

Tiagabine: efficacy and safety in partial seizures &ndash; current status
por: J&uuml;rgen Bauer, et al.
Publicado: (2008)

A CD8+ NK cell transcriptomic signature associated with clinical outcome in relapsing remitting multiple sclerosis
por: Eoin F. McKinney, et al.
Publicado: (2021)

Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing–remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis
por: Christopher Oldmeadow, et al.
Publicado: (2021)

Promising Effects of Vitex Agnus-Castus on Quality of Life and Sexual Function in Premenopausal Relapsing Remitting Multiple Sclerosis Patients
por: Sara Rahgooy, et al.
Publicado: (2020)

Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review
por: Sylwia Pietrasik, et al.
Publicado: (2021)

Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
por: Tran JQ, et al.
Publicado: (2016)

Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls.
por: Andreas Keller, et al.
Publicado: (2009)

Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis
por: Georgios Efthymiou, et al.
Publicado: (2017)

Cocaine-induced vasculitis: is this a new trend?
por: Garc&iacute;a P&eacute;rez MR, et al.
Publicado: (2013)

Central corneal thickness and anterior chamber depth measurement by Sirius&reg; Scheimpflug tomography and ultrasound
por: Jorge J, et al.
Publicado: (2013)

Treatment of Parkinson&#39;s disease: nanostructured sol&ndash;gel silica&ndash;dopamine reservoirs for controlled drug release in the central nervous system
por: Tessy L&oacute;pez, et al.
Publicado: (2010)

A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis
por: Kerstin Hellwig, et al.
Publicado: (2021)

Remitting long-standing major depression in a multiple sclerosis patient with several concurrent conditions
por: Sachinvala ND, et al.
Publicado: (2018)

Functionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapy
por: Cruz-Bustos T, et al.
Publicado: (2012)

Evolution of visual performance in 70 eyes implanted with the Tecnis&reg; ZMB00 multifocal intraocular lens
por: Palomino Bautista C, et al.
Publicado: (2012)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Richard A Rudick, et al.
Publicado: (2008)

Long-term treatment of patients with HIV-1: the role of atazanavir
por: Miguel &Aacute;ngel Artacho, et al.
Publicado: (2010)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Clemens Warnke, et al.
Publicado: (2009)

Neuropsychology of eating disorders: 1995–2012
por: J&aacute;uregui-Lobera I
Publicado: (2013)

Ligneous conjunctivitis in a patient with Crohn&prime;s disease
por: Graciana Fuentes-P&aacute;ez, et al.
Publicado: (2008)

Effect of 17&beta;-estradiol on olfactory bulbectomy-induced oxidative stress and behavioral changes in rats
por: Inmaculada Tasset, et al.
Publicado: (2008)